‘Pharma Admet Testing Market Worth $11.64bn In 2020’ Says Visiongain Report

16 August 2018
Pharma

Visiongain’s new report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies indicates that the pharma ADMET Testing market will see $11.64bn in spending in 2020.

The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.
The lead analyst of this report said “Revenues for the ADMET Testing market will continue to increase during the 2015-2027 period as drug developers focus on improving candidate selection. The market which was once dominated by in vivo and in vitro tests is steadily giving way to in silico methods as technological advances gain footing.
Growth will be driven by the drug development budget cuts and the push for better candidate selections. With an approximate 90% attrition rate in clinical development, drug developers are more inclined than ever to choose better candidates and avoid losing hundreds of millions of clinical trials.”
The 149-page report contains 100 charts that add visual analysis in order to explain the developing trends within the pharma ADMET Testing market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the pharma ADMET Testing market and its leading submarkets: In Vivo ADMET Testing, In Vitro ADMET Testing and In Silico ADMET Testing.
The 149-page report offers market forecasts for the leading regional and national markets: the US, Germany, France, The UK, Italy, Spain, Japan, China, Brazil, Russia, India, South Korea and RoW.
Moreover, our work discusses the leading companies in the pharma ADMET Testing market. Our study also includes SWOT and STEP analysis of this industry and market.

The report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies report will be of value to anyone who wants to better understand the pharma ADMET Testing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma ADMET Testing market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever